Cue Biopharma Stock Analysis
| CUE Stock | USD 0.96 0.01 1.03% |
Cue Biopharma is overvalued with Real Value of 0.86 and Hype Value of 0.96. The main objective of Cue Biopharma stock analysis is to determine its intrinsic value, which is an estimate of what Cue Biopharma is worth, separate from its market price. There are two main types of Cue Biopharma's stock analysis: fundamental analysis and technical analysis.
The Cue Biopharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Cue Biopharma's ongoing operational relationships across important fundamental and technical indicators.
Cue |
Cue Stock Analysis Notes
About 19.0% of the company shares are held by institutions such as insurance companies. The book value of Cue Biopharma was currently reported as 0.42. The company recorded a loss per share of 0.91. Cue Biopharma had not issued any dividends in recent years. Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Cue Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 57 people. For more info on Cue Biopharma please contact JD MSc at 617 949 2680 or go to https://www.cuebiopharma.com.Cue Biopharma Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Cue Biopharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Cue Biopharma or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Cue Biopharma had very high historical volatility over the last 90 days | |
| Cue Biopharma has some characteristics of a very speculative penny stock | |
| Cue Biopharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 5.49 M. Reported Net Loss for the year was (50.73 M) with loss before taxes, overhead, and interest of (27.76 M). | |
| Cue Biopharma has about 66.13 M in cash with (39.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Cue Biopharma Upcoming and Recent Events
| 19th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 19th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Cue Market Capitalization
The company currently falls under 'Micro-Cap' category with a total capitalization of 61.4 M.Technical Drivers
As of the 21st of March, Cue Biopharma shows the risk adjusted performance of 0.0204, and Mean Deviation of 4.79. Cue Biopharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Cue Biopharma coefficient of variation and the relationship between the jensen alpha and skewness to decide if Cue Biopharma is priced correctly, providing market reflects its regular price of 0.96 per share. Given that Cue Biopharma is a hitting penny stock territory we recommend to closely look at its total risk alpha.Cue Biopharma Price Movement Analysis
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Cue Biopharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Cue Biopharma. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Cue Biopharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cue Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cue Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cue Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cue Biopharma Outstanding Bonds
Cue Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cue Biopharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cue bonds can be classified according to their maturity, which is the date when Cue Biopharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Cue Biopharma Predictive Daily Indicators
Cue Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cue Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Cue Biopharma Forecast Models
Cue Biopharma's time-series forecasting models are one of many Cue Biopharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cue Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Cue Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Cue Biopharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cue shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Cue Biopharma. By using and applying Cue Stock analysis, traders can create a robust methodology for identifying Cue entry and exit points for their positions.
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Cue Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 57 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Cue Biopharma to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Efficient Frontier Now
Efficient FrontierPlot and analyze your portfolio and positions against risk-return landscape of the market. |
| All Next | Launch Module |
Complementary Tools for Cue Stock analysis
When running Cue Biopharma's price analysis, check to measure Cue Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cue Biopharma is operating at the current time. Most of Cue Biopharma's value examination focuses on studying past and present price action to predict the probability of Cue Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cue Biopharma's price. Additionally, you may evaluate how the addition of Cue Biopharma to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |